Meloxicam Teva

Meloxicam, the active ingredient in Meloxicam Teva, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as an oral tablet for oral use. It is indicated for the relief of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute musculoskeletal pain.

GNH USA supplies Meloxicam Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID that reduces inflammation and pain in several musculoskeletal conditions.

Osteoarthritis: alleviates joint pain and swelling, improving function. Rheumatoid arthritis: decreases inflammatory activity and joint damage progression. Ankylosing spondylitis: relieves spinal stiffness and pain. Acute pain: provides rapid analgesia for short‑term musculoskeletal discomfort.

Common Side Effects: - Nausea or upset stomach. - Diarrhea or loose stools. - Headache. - Dizziness.

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding. - Elevated liver enzymes or hepatitis. - Severe skin reactions such as Stevens‑Johnson syndrome. - Acute renal impairment or worsening of existing kidney disease. - Cardiovascular events including heart attack or stroke. - Anaphylactic or severe allergic reactions.

Before initiating therapy, consider the following safety measures. - Renal function: assess baseline kidney status and monitor periodically. - Blood pressure: watch for hypertension, especially in high‑risk patients. - Gastrointestinal risk: avoid in individuals with active peptic ulcer disease. - Concomitant anticoagulants: use caution due to increased bleeding risk. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Meloxicam may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Lithium: heightened lithium serum concentrations. - Methotrexate: potential for enhanced toxicity.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may exacerbate fluid and electrolyte disturbances. - Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding tendency.